vs

Side-by-side financial comparison of Solventum (SOLV) and Teradyne (TER). Click either name above to swap in a different company.

Solventum is the larger business by last-quarter revenue ($2.0B vs $1.1B, roughly 1.8× Teradyne). Teradyne runs the higher net margin — 23.7% vs 3.2%, a 20.6% gap on every dollar of revenue. On growth, Teradyne posted the faster year-over-year revenue change (43.9% vs -3.7%). Teradyne produced more free cash flow last quarter ($218.8M vs $32.0M). Over the past eight quarters, Teradyne's revenue compounded faster (34.4% CAGR vs -0.4%).

Solventum Corporation is an American health care company that was spun off from 3M on April 1, 2024.

Teradyne, Inc. is an American automatic test equipment (ATE) designer and manufacturer based in North Reading, Massachusetts. Its high-profile customers include Samsung, Qualcomm, Intel, Analog Devices, Texas Instruments and IBM.

SOLV vs TER — Head-to-Head

Bigger by revenue
SOLV
SOLV
1.8× larger
SOLV
$2.0B
$1.1B
TER
Growing faster (revenue YoY)
TER
TER
+47.6% gap
TER
43.9%
-3.7%
SOLV
Higher net margin
TER
TER
20.6% more per $
TER
23.7%
3.2%
SOLV
More free cash flow
TER
TER
$186.8M more FCF
TER
$218.8M
$32.0M
SOLV
Faster 2-yr revenue CAGR
TER
TER
Annualised
TER
34.4%
-0.4%
SOLV

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
SOLV
SOLV
TER
TER
Revenue
$2.0B
$1.1B
Net Profit
$63.0M
$257.2M
Gross Margin
51.4%
57.2%
Operating Margin
6.3%
27.1%
Net Margin
3.2%
23.7%
Revenue YoY
-3.7%
43.9%
Net Profit YoY
103.2%
75.9%
EPS (diluted)
$0.37
$1.62

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
SOLV
SOLV
TER
TER
Q4 25
$2.0B
$1.1B
Q3 25
$2.1B
$769.2M
Q2 25
$2.2B
$651.8M
Q1 25
$2.1B
$685.7M
Q4 24
$2.1B
$752.9M
Q3 24
$2.1B
$737.3M
Q2 24
$2.1B
$729.9M
Q1 24
$2.0B
$599.8M
Net Profit
SOLV
SOLV
TER
TER
Q4 25
$63.0M
$257.2M
Q3 25
$1.3B
$119.6M
Q2 25
$90.0M
$78.4M
Q1 25
$137.0M
$98.9M
Q4 24
$31.0M
$146.3M
Q3 24
$122.0M
$145.6M
Q2 24
$89.0M
$186.3M
Q1 24
$237.0M
$64.2M
Gross Margin
SOLV
SOLV
TER
TER
Q4 25
51.4%
57.2%
Q3 25
54.2%
58.4%
Q2 25
54.4%
57.2%
Q1 25
53.8%
60.6%
Q4 24
53.9%
59.4%
Q3 24
56.0%
59.2%
Q2 24
54.6%
58.3%
Q1 24
58.1%
56.6%
Operating Margin
SOLV
SOLV
TER
TER
Q4 25
6.3%
27.1%
Q3 25
80.6%
18.9%
Q2 25
9.9%
13.9%
Q1 25
7.3%
17.6%
Q4 24
6.6%
20.4%
Q3 24
13.2%
20.6%
Q2 24
11.7%
28.8%
Q1 24
18.9%
13.0%
Net Margin
SOLV
SOLV
TER
TER
Q4 25
3.2%
23.7%
Q3 25
60.4%
15.5%
Q2 25
4.2%
12.0%
Q1 25
6.6%
14.4%
Q4 24
1.5%
19.4%
Q3 24
5.9%
19.8%
Q2 24
4.3%
25.5%
Q1 24
11.8%
10.7%
EPS (diluted)
SOLV
SOLV
TER
TER
Q4 25
$0.37
$1.62
Q3 25
$7.22
$0.75
Q2 25
$0.51
$0.49
Q1 25
$0.78
$0.61
Q4 24
$0.18
$0.89
Q3 24
$0.70
$0.89
Q2 24
$0.51
$1.14
Q1 24
$1.37
$0.40

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
SOLV
SOLV
TER
TER
Cash + ST InvestmentsLiquidity on hand
$878.0M
$293.8M
Total DebtLower is stronger
$5.0B
Stockholders' EquityBook value
$5.0B
$2.8B
Total Assets
$14.3B
$4.2B
Debt / EquityLower = less leverage
1.00×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
SOLV
SOLV
TER
TER
Q4 25
$878.0M
$293.8M
Q3 25
$1.6B
$272.7M
Q2 25
$492.0M
$339.3M
Q1 25
$534.0M
$475.6M
Q4 24
$762.0M
$553.4M
Q3 24
$772.0M
$510.0M
Q2 24
$897.0M
$421.9M
Q1 24
$996.0M
$707.4M
Total Debt
SOLV
SOLV
TER
TER
Q4 25
$5.0B
Q3 25
$5.1B
Q2 25
$7.8B
Q1 25
$7.9B
Q4 24
$8.0B
Q3 24
$8.1B
Q2 24
$8.3B
Q1 24
$8.3B
Stockholders' Equity
SOLV
SOLV
TER
TER
Q4 25
$5.0B
$2.8B
Q3 25
$5.0B
$2.7B
Q2 25
$3.6B
$2.8B
Q1 25
$3.3B
$2.8B
Q4 24
$3.0B
$2.8B
Q3 24
$3.2B
$2.9B
Q2 24
$2.9B
$2.7B
Q1 24
$3.9B
$2.6B
Total Assets
SOLV
SOLV
TER
TER
Q4 25
$14.3B
$4.2B
Q3 25
$14.0B
$4.0B
Q2 25
$15.1B
$3.8B
Q1 25
$14.5B
$3.7B
Q4 24
$14.5B
$3.7B
Q3 24
$14.7B
$3.8B
Q2 24
$14.6B
$3.6B
Q1 24
$14.7B
$3.4B
Debt / Equity
SOLV
SOLV
TER
TER
Q4 25
1.00×
Q3 25
1.03×
Q2 25
2.14×
Q1 25
2.43×
Q4 24
2.71×
Q3 24
2.54×
Q2 24
2.90×
Q1 24
2.16×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
SOLV
SOLV
TER
TER
Operating Cash FlowLast quarter
$95.0M
$281.6M
Free Cash FlowOCF − Capex
$32.0M
$218.8M
FCF MarginFCF / Revenue
1.6%
20.2%
Capex IntensityCapex / Revenue
3.2%
5.8%
Cash ConversionOCF / Net Profit
1.51×
1.09×
TTM Free Cash FlowTrailing 4 quarters
$-10.0M
$450.4M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
SOLV
SOLV
TER
TER
Q4 25
$95.0M
$281.6M
Q3 25
$76.0M
$49.0M
Q2 25
$169.0M
$182.1M
Q1 25
$29.0M
$161.6M
Q4 24
$219.0M
$282.6M
Q3 24
$169.0M
$166.3M
Q2 24
$355.0M
$216.1M
Q1 24
$442.0M
$7.3M
Free Cash Flow
SOLV
SOLV
TER
TER
Q4 25
$32.0M
$218.8M
Q3 25
$-21.0M
$2.4M
Q2 25
$59.0M
$131.7M
Q1 25
$-80.0M
$97.6M
Q4 24
$92.0M
$225.2M
Q3 24
$76.0M
$114.4M
Q2 24
$297.0M
$171.2M
Q1 24
$340.0M
$-36.7M
FCF Margin
SOLV
SOLV
TER
TER
Q4 25
1.6%
20.2%
Q3 25
-1.0%
0.3%
Q2 25
2.7%
20.2%
Q1 25
-3.9%
14.2%
Q4 24
4.4%
29.9%
Q3 24
3.7%
15.5%
Q2 24
14.3%
23.5%
Q1 24
16.9%
-6.1%
Capex Intensity
SOLV
SOLV
TER
TER
Q4 25
3.2%
5.8%
Q3 25
4.6%
6.1%
Q2 25
5.1%
7.7%
Q1 25
5.3%
9.3%
Q4 24
6.1%
7.6%
Q3 24
4.5%
7.0%
Q2 24
2.8%
6.1%
Q1 24
5.1%
7.3%
Cash Conversion
SOLV
SOLV
TER
TER
Q4 25
1.51×
1.09×
Q3 25
0.06×
0.41×
Q2 25
1.88×
2.32×
Q1 25
0.21×
1.63×
Q4 24
7.06×
1.93×
Q3 24
1.39×
1.14×
Q2 24
3.99×
1.16×
Q1 24
1.86×
0.11×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

SOLV
SOLV

Infection Prevention And Surgical Solutions$752.0M38%
Cost Of Software And Rentals$508.0M25%
Health Information Systems Segment$347.0M17%
Dental Solutions Segment$343.0M17%
Related Party$14.0M1%

TER
TER

Soc$646.5M60%
Memory$206.5M19%
Transferred At Point In Time$90.0M8%
Universal Robots$89.4M8%
IST$30.5M3%
Transferred Over Time$20.5M2%

Related Comparisons